People

Kody Kinsley advises Cortica on strategy. He previously served as North Carolina’s health and human services secretary, working on Medicaid expansion, behavioral healthcare and medical debt. His current published biography also identifies advisory affiliations with Johns Hopkins and the Milken Institute.

Kevin Shapiro co-directs the Cortica Innovation Network and leads research and therapeutic technologies. A pediatric neurologist and cognitive-neuroscience researcher, he studies brain development, speech, language and early brain injury. He earned medical and doctoral degrees at Harvard.

Elysa Marco co-directs the Cortica Innovation Network and practices pediatric cognitive and behavioral neurology. Her research addresses sensory processing, neurodevelopmental genetics, brain anatomy and treatment. She previously led sensory and autism programs at UCSF.

Cindy Watson became Cortica’s COO in 2026, leading operations across the company. She previously served as Wellpath’s COO and has led healthcare organizations through several stages of growth. Her academic training is in communication disorders.

Chris Hollander joined Cortica as chief marketing officer in 2025, leading marketing, partnerships, communications and enrollment. His earlier marketing leadership includes Amazon One Medical, Iora Health and Panera Bread. He also advises .406 Ventures and holds a Duke MBA.

Benjamin Nathan leads technology and transformation at Cortica, including electronic records, software, analytics and information security. He previously led technology at UCLA’s medical school and served as deputy CIO at Weill Cornell. He holds a Columbia technology-management master’s degree.

Marc Spooner leads Cortica’s strategy, payer negotiations, analytics and value-based contracting. He previously served as COO of Point32Health and led commercial and government products at Tufts Health Plan. He studied at Harvard Business School and Duke.

Briana Elvaiah is Cortica’s CFO, overseeing finance, revenue-cycle management and human resources. She previously led finance at Correctional Medical Group Companies and Vericare, working in healthcare services and technology. She studied accounting at the University of San Diego.

Neil Hattangadi is Cortica’s co-founder and CEO. His background combines physician and scientific training with medical-device and biotechnology leadership, including Spirox and Volcano. He studied at Duke, Harvard Medical School and Oxford as a Rhodes Scholar.

Suzanne Goh co-founded Cortica and leads its medical practice. A pediatric behavioral neurologist, behavior analyst and neuroscience researcher, she developed the Cortica care model and has studied metabolic features, brain chemistry and neural circuitry in autism. She trained at Harvard, Oxford, UCSF and Columbia.

Juvena Therapeutics board observer representing MAK Capital; also serves on MARAbio's board. Has investment, corporate development and legal experience.

SV Health Investors venture partner and ViaNautis chief scientific officer, with immunology and drug discovery experience; previously chief scientific officer at Mestag Therapeutics, Enara Bio and TRexBio.

Neurorehabilitation researcher and Shepherd Center research leader; also serves on the SCI Ventures board.

Neurosurgeon and biomedical-device researcher at the University of Calgary, with training in biomedical engineering and cerebrovascular surgery.

Calgary neurosurgeon specializing in brain aneurysms and stroke; co-founded Fluid Biomed with Alim Mitha.

Alan Flores-Lopez is published by Neo as Lumos Co-Founder. This is a publicly listed external mentoring or applicant-interviewing affiliation, not an assertion of employment by Neo or a personal investment.

Raymond W. Cohen is a medical-device executive and former Axonics co-founder and CEO. Sherpa Healthcare Partners appointed him venture partner in January 2025 following Axonics’ acquisition by Boston Scientific. His current Resonant Link Medical biography corroborates the Sherpa venture affiliation and identifies his board chair role there. Institutional investment amounts are not personal investments inferred from his board positions.

Alex Amen is a biomedical scientist and PsyMed adviser with gene and cell therapy expertise. Her experience includes therapeutic asset acquisition and postdoctoral research in Jennifer Doudna’s laboratory.

Chrystal Mavros is a PsyMed adviser. The firm describes her Columbia University microbiology work spanning gene therapy, the gut–brain relationship, sequencing and postmortem brain analysis.

Registered patent attorney and founder of Calyx Law, advising on intellectual property involving psychedelics and related technologies.

Draig Therapeutics scientific advisory board member and Yale University professor and chair of psychiatry, with neuroscience and psychiatric drug development expertise.

Dina Burkitbayeva co-founded PsyMed Ventures. The firm also identifies her leadership of Freedom Biosciences, which develops neuropsychiatric therapeutics.

Martina Galdos works on operations at PsyMed Ventures. Her experience spans startup operations, sales enablement and product marketing, with a focus on applying AI to operational workflows.

Christopher Luzzio serves Madison Scientific as Co-Founder, Advisor. The company identifies him as a cofounder and neurologist associated with the University of Wisconsin School of Medicine and Public Health.

David Hsu serves Madison Scientific as Co-Founder, Advisor. The company identifies him as a cofounder and professor of neurology associated with the University of Wisconsin–Madison.

Josh Medow serves Madison Scientific as Co-Founder, Board Member. The current issuer directory confirms this role; an expanded professional biography is not published there.

Michael Nagy serves Madison Scientific as Chief Technology Officer. The current issuer directory confirms this role; an expanded professional biography is not published there.

Medical technology entrepreneur and investor. Madison Scientific's own leadership directory identifies Tyler Wanke, MD, MBA, MEM, as its president, CEO and cofounder. Northwestern Kellogg's October2026 speaker announcement identifies him separately as managing director of Dendrion Ventures. SEC filings name him executive of several Dendrion venture vehicles.

Sandi Lam serves Madison Scientific as Advisor. The company biography describes her neurosurgery leadership and pediatric neurosurgery professorship at Northwestern University Feinberg School of Medicine; no separately dated institutional appointment is inferred.

Former Nexus NeuroTech Ventures general partner and co-founder. Previously president of medical devices at Verily and a neuromodulation R&D leader at Boston Scientific; currently a trusted adviser at Ground Effect Ventures.